Ischemic stroke
Conditions
Interventions
DAPT group:Cilostazol 100mg bid + Aspirin 100mg qd / Clopidogrel 75mg qd
SAPT group:Aspirin 100mg qd / Clopidogrel 75mg qd
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Patients with acute ischemic stroke or TIA within 90 days of onset; 2. Age between 18 and 85 years inclusive; 3. Pre-stroke mRS score of 2 or less; 4. Symptomatic intracranial arterial stenosis diagnosed by CTA or MRA (internal carotid artery segments C6-7, anterior cerebral artery segments A1-2, middle cerebral artery segments M1-2, vertebral artery segment V4, basilar artery, posterior cerebral artery segments P1-2), with a stenosis rate of 50% to 99%; 5. Receiving dual antiplatelet therapy with aspirin and clopidogrel, as per the SAMMPRIS study; 6. Informed consent obtained.
Exclusion criteria
Exclusion criteria: 1. Suspected sources of cardiogenic thrombus, such as paroxysmal atrial fibrillation, infective endocarditis, and post-valve replacement surgery; 2. History of responsible intracranial artery stenting/angioplasty, or planned surgery within 6 months; 3. Concurrent extracranial artery stenosis with a stenosis rate of =50%; 4. Concurrent non-atherosclerotic intracranial arterial diseases, including but not limited to intracranial arterial dissection, moyamoya disease, arteriovenous malformations, aneurysms, vasculitis, etc.; 5. History of intracranial hemorrhage within the past 3 months; 6. Active bleeding disorders, coagulation dysfunction, or other bleeding tendencies; 7. Severe hepatic or renal insufficiency; 8. Any degree of heart failure; 9. Concurrent other severe medical conditions, cognitive or psychiatric disorders that prevent self-care, or life expectancy =3 years; 10. Contraindications to magnetic resonance imaging such as internal metal implants, contrast agent allergies, etc.; 11. Allergy or severe intolerance to the components of the trial medication; 12. Pregnant or lactating women; 13. Assessed by the investigator as unsuitable for this study, or participation in this study would be detrimental; 14. Currently participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage change in plaque burden from baseline to 12 months after onset; | — |
Countries
China
Contacts
Public ContactXin Cheng
Huashan Hospital, Fudan University
Outcome results
None listed